anmelden
OMX Copenhagen 20
1.539,57
PKT
+38,10
PKT
+2,54
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 21.05.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 19.05.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 13.05.21 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 12.05.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.05.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 06.05.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 06.05.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 06.05.21 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 06.05.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 06.05.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.05.21 | Novo Nordisk overweight | Barclays Capital | |
| 05.05.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.05.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.04.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 28.04.21 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 14.04.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 13.04.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 25.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 23.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 23.03.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 23.03.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 19.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 10.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 04.03.21 | Novo Nordisk Conviction Buy | Goldman Sachs Group Inc. | |
| 22.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 18.02.21 | Novo Nordisk Neutral | UBS AG | |
| 16.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 11.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 10.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 09.02.21 | Novo Nordisk buy | Deutsche Bank AG |